Please enable JavaScript to continue using this application.

Compare $FDMT vs $PRME | Chartloom

Compare

$FDMT vs $PRME

4D Molecular Therapeutics Inc · Prime Medicine Inc

FDMT

4D Molecular Therapeutics Inc

PRME

Prime Medicine Inc

Compare $FDMT vs $PRME

Comparing 4D Molecular Therapeutics Inc and Prime Medicine Inc

FDMT4D Molecular Therapeutics Inc

PRMEPrime Medicine Inc

FDMT4D Molecular Therapeutics Inc

Market cap

$697M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

50.39x

Rev growth (TTM)

278712.1%

YTD performance

82.1%

52W performance

38.0%

FCF yield

-22.4%

PRMEPrime Medicine Inc

Market cap

$721M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

126.79x

Rev growth (TTM)

-17.9%

YTD performance

13.0%

52W performance

-38.1%

FCF yield

-21.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FDMT

PRME

Detailed metrics comparison

FDMT

4D Molecular Therapeutics Inc

PRME

Prime Medicine Inc

Market Cap

FDMT$697M

PRME$721M

Enterprise Value

FDMT$646M

PRME$673M

Price

FDMT$13.33

PRME$3.99

P/E Ratio

FDMTN/A

PRMEN/A

P/S Ratio

FDMT7.57x

PRME176.94x

EV/Sales

FDMT7.02x

PRME165.29x

EV/EBITDA

FDMT0.00x

PRME0.00x

P/B Ratio

FDMT1.85x

PRME13.58x

P/FCF Ratio

FDMTN/A

PRMEN/A

EV/FCF

FDMT-4.13x

PRME-4.29x

PEG Ratio

FDMTN/A

PRMEN/A

Forward P/E (NTM)

FDMTN/A

PRMEN/A

Forward P/S (NTM)

FDMT50.39x

PRME126.79x

Revenue (TTM)

FDMT$92M

PRME$4M

Revenue Growth (YoY)

FDMT278712.1%

PRME-17.9%

Forward Rev Growth

FDMT40.6%

PRME22.7%

Gross Margin (TTM)

FDMT0.0%

PRME0.0%

Operating Margin (TTM)

FDMT0.0%

PRME0.0%

EBITDA Margin (TTM)

FDMT-208.8%

PRME-4643.3%

Net Margin (TTM)

FDMT-194.7%

PRME-4613.1%

FCF Margin (TTM)

FDMT-169.9%

PRME-3850.9%

Net Income (TTM)

FDMT$-179M

PRME$-188M

FCF (TTM)

FDMT$-156M

PRME$-157M

EPS (TTM)

FDMT-$2.55

PRME-$1.06

ROE (TTM)

FDMT-4133.0%

PRME-18827.0%

ROA (TTM)

FDMT-3590.0%

PRME-5911.0%

ROIC (TTM)

FDMT-4087.0%

PRME-18827.0%

Cash

FDMT$70M

PRME$47M

Debt

FDMT$20M

PRME$0

Net Cash/Debt

FDMT$51M

PRME$47M

Current Ratio (TTM)

FDMT8.03x

PRME3.05x

Quick Ratio (TTM)

FDMT7.68x

PRME3.01x

Debt/Equity (TTM)

FDMT0.05x

PRME0.00x

Debt/Assets (TTM)

FDMT0.0%

PRME0.0%

Interest Coverage (TTM)

FDMTN/A

PRMEN/A

Net Debt/EBITDA (TTM)

FDMT0.00x

PRME0.00x

Beta

FDMT2.90

PRME2.35

52W Performance

FDMT38.0%

PRME-38.1%

YTD Performance

FDMT82.1%

PRME13.0%

% from 52W High

FDMT-21.3%

PRME-40.0%

% from 52W Low

FDMT91.5%

PRME49.4%

Asset Turnover (TTM)

FDMT0.18x

PRME0.01x

FCF Yield (TTM)

FDMT-22.4%

PRME-21.8%

Earnings Yield (TTM)

FDMT-25.7%

PRME-26.1%

Dividend Yield (TTM)

FDMTN/A

PRMEN/A

Rule of 40

FDMT278,542.3

PRME-3,868.8

EV/GP/RG

FDMTN/A

PRMEN/A

Ticker research

View FDMT research View PRME research

Metric	FDMT 4D Molecular Therapeutics Inc	PRME Prime Medicine Inc
Market & Valuation
Market Cap	$697M	$721M
Enterprise Value	$646M	$673M
Price	$13.33	$3.99
P/E Ratio	N/A	N/A
P/S Ratio	7.57x	176.94x
EV/Sales	7.02x	165.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.85x	13.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.13x	-4.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	50.39x	126.79x
Revenue & Growth
Revenue (TTM)	$92M	$4M
Revenue Growth (YoY)	278712.1%	-17.9%
Forward Rev Growth	40.6%	22.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-208.8%	-4643.3%
Net Margin (TTM)	-194.7%	-4613.1%
FCF Margin (TTM)	-169.9%	-3850.9%
Net Income (TTM)	$-179M	$-188M
FCF (TTM)	$-156M	$-157M
EPS (TTM)	-$2.55	-$1.06
ROE (TTM)	-4133.0%	-18827.0%
ROA (TTM)	-3590.0%	-5911.0%
ROIC (TTM)	-4087.0%	-18827.0%
Financial Health
Cash	$70M	$47M
Debt	$20M	$0
Net Cash/Debt	$51M	$47M
Current Ratio (TTM)	8.03x	3.05x
Quick Ratio (TTM)	7.68x	3.01x
Debt/Equity (TTM)	0.05x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.90	2.35
52W Performance	38.0%	-38.1%
YTD Performance	82.1%	13.0%
% from 52W High	-21.3%	-40.0%
% from 52W Low	91.5%	49.4%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.01x
FCF Yield (TTM)	-22.4%	-21.8%
Earnings Yield (TTM)	-25.7%	-26.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	278,542.3	-3,868.8
EV/GP/RG	N/A	N/A
Ticker research	View FDMT research	View PRME research

Valuation

P/S Ratio

FDMT

7.57x

PRME

176.94x

EV/FCF

PRME

-4.29x

FDMT

-4.13x

Growth & revenue

Revenue Growth TTM

FDMT

278712.1%

PRME

-17.9%

Forward Revenue Growth

FDMT

40.6%

PRME

22.7%

Profitability & performance

Gross Margin

FDMT

0.0%

PRME

0.0%

ROE

FDMT

-4133.0%

PRME

-18827.0%

FCF Yield %

PRME

-21.8%

FDMT

-22.4%

52-Week Performance

FDMT

38.0%

PRME

-38.1%

Detailed metrics comparison

FDMT

4D Molecular Therapeutics Inc

PRME

Prime Medicine Inc

Market Cap

FDMT$697M

PRME$721M

Enterprise Value

FDMT$646M

PRME$673M

Price

FDMT$13.33

PRME$3.99

P/E Ratio

FDMTN/A

PRMEN/A

P/S Ratio

FDMT7.57x

PRME176.94x

EV/Sales

FDMT7.02x

PRME165.29x

EV/EBITDA

FDMT0.00x

PRME0.00x

P/B Ratio

FDMT1.85x

PRME13.58x

P/FCF Ratio

FDMTN/A

PRMEN/A

EV/FCF

FDMT-4.13x

PRME-4.29x

PEG Ratio

FDMTN/A

PRMEN/A

Forward P/E (NTM)

FDMTN/A

PRMEN/A

Forward P/S (NTM)

FDMT50.39x

PRME126.79x

Revenue (TTM)

FDMT$92M

PRME$4M

Revenue Growth (YoY)

FDMT278712.1%

PRME-17.9%

Forward Rev Growth

FDMT40.6%

PRME22.7%

Gross Margin (TTM)

FDMT0.0%

PRME0.0%

Operating Margin (TTM)

FDMT0.0%

PRME0.0%

EBITDA Margin (TTM)

FDMT-208.8%

PRME-4643.3%

Net Margin (TTM)

FDMT-194.7%

PRME-4613.1%

FCF Margin (TTM)

FDMT-169.9%

PRME-3850.9%

Net Income (TTM)

FDMT$-179M

PRME$-188M

FCF (TTM)

FDMT$-156M

PRME$-157M

EPS (TTM)

FDMT-$2.55

PRME-$1.06

ROE (TTM)

FDMT-4133.0%

PRME-18827.0%

ROA (TTM)

FDMT-3590.0%

PRME-5911.0%

ROIC (TTM)

FDMT-4087.0%

PRME-18827.0%

Cash

FDMT$70M

PRME$47M

Debt

FDMT$20M

PRME$0

Net Cash/Debt

FDMT$51M

PRME$47M

Current Ratio (TTM)

FDMT8.03x

PRME3.05x

Quick Ratio (TTM)

FDMT7.68x

PRME3.01x

Debt/Equity (TTM)

FDMT0.05x

PRME0.00x

Debt/Assets (TTM)

FDMT0.0%

PRME0.0%

Interest Coverage (TTM)

FDMTN/A

PRMEN/A

Net Debt/EBITDA (TTM)

FDMT0.00x

PRME0.00x

Beta

FDMT2.90

PRME2.35

52W Performance

FDMT38.0%

PRME-38.1%

YTD Performance

FDMT82.1%

PRME13.0%

% from 52W High

FDMT-21.3%

PRME-40.0%

% from 52W Low

FDMT91.5%

PRME49.4%

Asset Turnover (TTM)

FDMT0.18x

PRME0.01x

FCF Yield (TTM)

FDMT-22.4%

PRME-21.8%

Earnings Yield (TTM)

FDMT-25.7%

PRME-26.1%

Dividend Yield (TTM)

FDMTN/A

PRMEN/A

Rule of 40

FDMT278,542.3

PRME-3,868.8

EV/GP/RG

FDMTN/A

PRMEN/A

Ticker research

View FDMT research View PRME research

Metric	FDMT 4D Molecular Therapeutics Inc	PRME Prime Medicine Inc
Market & Valuation
Market Cap	$697M	$721M
Enterprise Value	$646M	$673M
Price	$13.33	$3.99
P/E Ratio	N/A	N/A
P/S Ratio	7.57x	176.94x
EV/Sales	7.02x	165.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.85x	13.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.13x	-4.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	50.39x	126.79x
Revenue & Growth
Revenue (TTM)	$92M	$4M
Revenue Growth (YoY)	278712.1%	-17.9%
Forward Rev Growth	40.6%	22.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-208.8%	-4643.3%
Net Margin (TTM)	-194.7%	-4613.1%
FCF Margin (TTM)	-169.9%	-3850.9%
Net Income (TTM)	$-179M	$-188M
FCF (TTM)	$-156M	$-157M
EPS (TTM)	-$2.55	-$1.06
ROE (TTM)	-4133.0%	-18827.0%
ROA (TTM)	-3590.0%	-5911.0%
ROIC (TTM)	-4087.0%	-18827.0%
Financial Health
Cash	$70M	$47M
Debt	$20M	$0
Net Cash/Debt	$51M	$47M
Current Ratio (TTM)	8.03x	3.05x
Quick Ratio (TTM)	7.68x	3.01x
Debt/Equity (TTM)	0.05x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.90	2.35
52W Performance	38.0%	-38.1%
YTD Performance	82.1%	13.0%
% from 52W High	-21.3%	-40.0%
% from 52W Low	91.5%	49.4%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.01x
FCF Yield (TTM)	-22.4%	-21.8%
Earnings Yield (TTM)	-25.7%	-26.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	278,542.3	-3,868.8
EV/GP/RG	N/A	N/A
Ticker research	View FDMT research	View PRME research